Amgen, Inc. vs BHP Billiton Limited — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while BHP Billiton Limited trades at $90.77 (market cap $229.15B). The key difference: Amgen, Inc. and BHP Billiton Limited are close in size by market cap, and BHP Billiton Limited pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| AMGN | BHP | |
|---|---|---|
Market Cap | $224.14B | $229.15B |
Sector | Health | Basic Materials |
52-Week High | $417.20 | $93.15 |
52-Week Low | $271.18 | $52.14 |
Enterprise Value | $267.45B | $243.35B |
Dividend Yield | 2.43% | 2.95% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →